AstraZeneca will take full control of Caelum Biosciences in a deal worth up to $500 million, the drugmaker said on Wednesday, sharpening its focus on rare-disease drugs following its purchase of Alexion Pharmaceuticals. The deal gives AstraZeneca access to another potentially lucrative rare disease drug that is undergoing late-stage trials and has a “fast track”…